To include your compound in the COVID-19 Resource Center, submit it here.
In a placebo-controlled U.S. Phase II trial in 319 patients, oral tolvaptan significantly decreased body
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury